GlassScriptPhysician profile
Tracey L Cunningham
NPI 1275942245
$1,286.23
in general payments reported to CMS, 2019-2025
21 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $487 · 2023: $191 · 2024: $187 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $335.40 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.09 | 2021-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $131.14 | 2021-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.38 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $90.48 | 2021-2025 | Rexulti |
| Lundbeck LLC | $86.42 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $63.08 | 2021-2022 | |
| Lilly USA, LLC | $47.68 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $46.15 | 2022-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $32.14 | 2022 | |
| Exact Sciences Corporation | $31.60 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $23.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.52 | 2025 | Breztri |
| Alkermes, INC. | $21.64 | 2022 | |
| Almatica Pharma LLC | $19.49 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.87 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $18.47 | 2021 | |
| Novo Nordisk INC | $17.46 | 2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $16.99 | 2023 | Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $16.97 | 2024 | Quviviq |
| Bausch Health US, LLC | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.